Akebia Therapeutics (AKBA) Tax Provisions (2018 - 2026)

Akebia Therapeutics' (AKBA) quarterly Tax Provisions came in at $126000.0 in Q1 2026, down 87.51% on a QoQ basis from $1.0 million in Q4 2025.

Akebia Therapeutics (AKBA) Tax Provisions (2018 - 2026) Analysis & Trends

Akebia Therapeutics (AKBA) has 4 years of Tax Provisions data on file, last reported at $126000.0 in Q1 2026.

On a quarterly basis, Tax Provisions changed N/A year-over-year to $126000.0 in Q1 2026; TTM through Mar 2026 was $1.8 million, a N/A change from a year earlier, with the FY2025 full-year figure at $1.6 million, changed N/A from the prior year.
Tax Provisions for Q1 2026 stood at $126000.0, down from $1.0 million in the prior quarter.
Over the last five years, Tax Provisions for AKBA reached as high as $1.0 million in Q4 2025 and fell as low as $126000.0 in Q1 2026.

#	Company	Market Cap	Enterprise Value	Gross Profit (Qtr)	Taxes (Qtr)
1	Haleon	87.22 Bn	85.35 Bn	-	-
2	Teva Pharmaceutical Industries	39.60 Bn	35.87 Bn	1.97 Bn	67.00 Mn
3	Zoetis	31.46 Bn	29.52 Bn	1.62 Bn	157.00 Mn
4	Takeda Pharmaceutical	26.49 Bn	22.44 Bn	4.39 Bn	676.90 Mn
5	United Therapeutics	23.03 Bn	20.88 Bn	648.10 Mn	43.40 Mn
6	Universe Pharmaceuticals	23.03 Bn	-10.56 Bn	-	-
7	Viatris	20.90 Bn	19.09 Bn	1.16 Bn	-423.70 Mn
8	Neurocrine Biosciences	17.50 Bn	16.19 Bn	800.70 Mn	48.90 Mn
9	Elanco Animal Health	12.33 Bn	11.91 Bn	785.00 Mn	30.00 Mn
10	Akebia Therapeutics	325.80 Mn	163.20 Mn	41.25 Mn	126,000.00

Download Data